ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1924

Characteristics of Lupus Nephritis in a Cross-Sectional Study of Hispanic and Native American Patients in New Mexico

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Vondenberg, Jaime (James) A., University of New Mexico, Albuquerque, New Mexico, United States
  • Shaffi, Saeed Kamran, University of New Mexico, Albuquerque, New Mexico, United States

In patients with lupus, nephritis develops in ~50% of patients, and is associated with significant morbidity. Therefore, it is important to characterize the demographic and biochemical variables associated with lupus nephritis. In this cross-sectional study comprised of many Hispanics and Native Americans, we investigate the demographic and biochemical variables at the time of lupus nephritis diagnosis.


We identified 62 patients with lupus nephritis from the University of New Mexico kidney biopsy registry that contains biopsies from 2002-2016. Demographics, comorbidities, outcomes, therapies, and laboratory data typically followed in lupus patients (complements, spot urine protein/creatinine (Pr/Cr) ratio, urine RBCs, serologies, etc) were collected from the registry and medical charts.


62 patients were included, 53 females and 9 males. White, Hispanic, and Native American races accounted for 35.5%, 30.6%, and 16.1% of the cohort, while 56.6% of patients identified ethnically as Hispanic. 3 patients had no labs. Overall mean age at the time of renal biopsy was 34.5 (SD 15.3) years old. Laboratory data among ethnicities is shown in Figure 1. Class IV was the most common classification in the whole cohort (48.5%), for Hispanics (56.7%), and Non-Hispanics (30%). Antibody status was similar among all ethnicities: ANA positive (95%; 80% titer ≥ 1:80), anti-dsDNA positive (73%), anti-Smith positive (56%), and SS-A positive (56%). The most common comorbidities were hypertension (n=46) and depression (n=16). For induction therapy, most Hispanics received low dose cyclophosphamide (CYC) (41%), and Non-Hispanics received mycophenolate mofetil (MMF) (35%). For maintenance therapy, both Hispanics (37%) and Non-Hispanics (35%) most often received MMF. 7 patients progressed to ESKD, by ethnicity: 5 Hispanic and 2 Unavailable (1 African American).


The lupus cohort predominantly consisted of females and class IV nephritis. Many patients of Hispanic ethnicity identified as White with respect to race. At the time of lupus nephritis diagnosis, antibody status, serum creatinine, and urine spot protein/creatinine ratio were similar among ethnicities. Hispanics were more likely to progress to ESKD. The most commonly used induction therapy was low dose CYC followed by MMF, and the most common maintenance therapy was MMF.